Propella Announces First Patient Dosed in Phase 1/2a Trial of PRL-02 for Treatment of Metastatic Prostate Cancer

NEXT STORY
Catalyst Pharmaceuticals Appoints Pharmaceutical Executive Molly Harper to its Board of Directors
PREV STORY
CicloMed Announces Initiation of Phase 1B Trial of Fosciclopirox in Newly Diagnosed and Recurrent Urothelial Cancer Patients
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Fulgent Genetics Reports First Quarter 2020 Financial Results

author_avatar
NASDAQ Market News

Atossa Therapeutics CEO Dr. Steven Quay to Participate in Panel Discussion at Cello Health’s Cancer Progress Virtual Conference on May 6, 2021

author_avatar
NASDAQ Market News

Jounce Therapeutics to Present Two Posters from the JTX-4014 and Vopratelimab Programs at the Society for Immunotherapy of Cancer’s (SITC) 34th Annual Meeting

author_avatar
NASDAQ Market News